Peter Serno
20Patents
9h-index
59Co-inventors
78Inventor score
Filing activity: Oct 18, 1984 → Dec 23, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6362178B1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | Chemistry; Metallurgy | 73 | Expired |
| US4711902A | Medicament formulation | Human Necessities | 52 | Expired |
| US4957922A | Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-di-hydro-4-oxo-7-(1-piperazinyl)-quinoline-3- carboxylic acid | Human Necessities | 43 | Expired |
| US5653998A | Injectable liposomal pharmaceutical preparations | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5023257A | Intramuscular injection forms of gyrase inhibitors | Human Necessities | 15 | Expired |
| US6566360B1 | 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors | Chemistry; Metallurgy | 13 | Expired |
| US6890922B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | Chemistry; Metallurgy | 10 | Expired |
| US5707655A | Process for the preparation of medicament formulations with controlled release | Human Necessities | 9 | Expired |
| US7696206B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | Chemistry; Metallurgy | 9 | Active |
| US8613950B2 | Pharmaceutical forms with improved pharmacokinetic properties | Human Necessities | 8 | Active |
| US7314871B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension | Chemistry; Metallurgy | 5 | Expired |
| US4976964A | Medicament formulation containing dihydropyridines and a process for its preparation | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7704999B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | Chemistry; Metallurgy | 3 | Active |
| US10905667B2 | Orally administrable modified-release pharmaceutical dosage form | Chemistry; Metallurgy | 2 | Active |
| US8273876B2 | Medicaments containing vardenafil hydrochloride trihydrate | Emerging Cross-Sectional Technologies | 2 | Active |
| US11344519B2 | Orally administrable modified-release pharmaceutical dosage form | Chemistry; Metallurgy | 0 | Active |
| US9655887B2 | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception | Human Necessities | 0 | Active |
| US8841446B2 | Medicaments containing vardenafil hydrochloride trihydrate | Emerging Cross-Sectional Technologies | 0 | Active |
| US6740306B2 | Imidazotriazinone-containing compositions for nasal administration | Human Necessities | 0 | Expired |
| US9579330B2 | Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.